Gerinnungsstörungen bei Leberzirrhose – Diagnostik und Management

Zusammenfassung

Patienten mit Leberzirrhose weisen komplexe Veränderungen des hämostatischen Systems auf, die sowohl mit Blutungs- als auch mit thrombotischen Komplikationen einhergehen können und im Rahmen des klinischen Managements berücksichtigt werden sollten.

Während eine prophylaktische Korrektur abnormaler Gerinnungsparameter vermieden werden sollte, ist vor invasiven Prozeduren ein individualisiertes Vorgehen zu empfehlen, wobei sich spezifische Präventionsmaßnahmen zur Stabilisierung der Gerinnung am periprozeduralen Blutungsrisiko orientieren sollten.

Weiterhin gilt zu beachten, dass sich die hämostatischen Veränderungen in Abhängigkeit des Stadiums der Erkrankung unterscheiden. Während sich das hämostatische System bei kompensierter Zirrhose oftmals in einem Gleichgewicht befindet, kann das Auftreten einer akuten Dekompensation zu einer Destabilisierung dieses Zustands führen.

Da konventionelle Gerinnungstests die komplexen Veränderungen des hämostatischen Systems bei Zirrhose nicht adäquat erfassen, können funktionelle Analysemethoden, wie viskoelastische Testverfahren oder Thrombingenerierungstests bei der Evaluation des Gerinnungsstatus hilfreich sein.

Die vorliegende Übersichtsarbeit beschreibt die zugrunde liegenden pathophysiologischen Veränderungen des hämostatischen Systems bei Leberzirrhose, liefert einen Überblick über geeignete Diagnostikmethoden und thematisiert Therapiemaßnahmen im Falle von Blutungs- und thrombotischen Komplikationen.

Abstract

Patients with liver cirrhosis often exhibit complex alterations in their hemostatic system that can be associated with both bleeding and thrombotic complications. While prophylactic correction of abnormal coagulation parameters should be avoided, an individualized approach is recommended prior to invasive procedures, whereby specific preventive measures to stabilize hemostasis should be based on the periprocedural bleeding risk. While the haemostatic system of patients with compensated cirrhosis is often in a rebalanced haemostatic state due to a parallel decline in both pro- and anti-haemostatic factors, a decompensation of liver cirrhosis can lead to destabilization of this fragile equilibrium. Since conventional coagulation tests do not adequately capture the complex changes in the hemostatic system in cirrhosis, functional analysis methods such as viscoelastic tests or thrombin generation assays can be used for evaluating the coagulation status. This review describes the underlying pathophysiological changes in the hemostatic system in liver cirrhosis, provides an overview of diagnostic methods and discusses therapeutic measures in case of bleeding and thrombotic complications.

Schlüsselwörter

Hepatische Koagulopathie - Hämostase - Thrombozytopenie - Blutung - viskoelastische Testverfahren

Keywords

hepatic coagulopathy - thrombocytopenia - liver cirrhosis - bleeding - viscoelastic tests

Publication History

Article published online:
02 August 2024

• Literatur

• 1 Lisman T, Porte RJ. Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases. Res Pract Thromb Haemost 2017; 1: 150-161 DOI: 10.1002/rth2.12028.
• 2 Lisman T, Caldwell SH, Intagliata NM. Haemostatic alterations and management of haemostasis in patients with cirrhosis. J Hepatol 2022; 76: 1291-1305 DOI: 10.1016/j.jhep.2021.11.004.
• 3 European Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol 2022; 76: 1151-1184 DOI: 10.1016/j.jhep.2021.09.003.
• 4 Rautou P-E, Caldwell SH, Villa E. Bleeding and Thrombotic Complications in Patients With Cirrhosis: A State-of-the-Art Appraisal. Clin Gastroenterol Hepatol 2023; 21: 2110-2123 DOI: 10.1016/j.cgh.2023.04.016.
• 5 Zanetto A, Northup P, Roberts L. et al. Haemostasis in cirrhosis: Understanding destabilising factors during acute decompensation. J Hepatol 2023; 78: 1037-1047 DOI: 10.1016/j.jhep.2023.01.010.
• 6 Dabbagh O, Oza A, Prakash S. et al. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 2010; 137: 1145-1149 DOI: 10.1378/chest.09-2177.
• 7 Søgaard KK, Horváth-Puhó E, Grønbaek H. et al. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104: 96-101 DOI: 10.1038/ajg.2008.34.
• 8 Xu S, Guo X, Yang B. et al. Evolution of Nonmalignant Portal Vein Thrombosis in Liver Cirrhosis: A Pictorial Review. Clin Transl Gastroenterol 2021; 12: e00409 DOI: 10.14309/ctg.0000000000000409.
• 9 Northup PG, Garcia-Pagan JC, Garcia-Tsao G. et al. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 73: 366-413 DOI: 10.1002/hep.31646.
• 10 Violi F, Basili S, Raparelli V. et al. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?. J Hepatol 2011; 55: 1415-1427 DOI: 10.1016/j.jhep.2011.06.008.
• 11 van Dievoet M-A, Eeckhoudt S, Stephenne X. Primary Hemostasis in Chronic Liver Disease and Cirrhosis: What Did We Learn over the Past Decade?. Int J Mol Sci 2020; 21 DOI: 10.3390/ijms21093294.
• 12 van den Boom BP, Lisman T. Pathophysiology and management of bleeding and thrombosis in patients with liver disease. Int J Lab Hematol 2022; 44: 79-88 DOI: 10.1111/ijlh.13856.
• 13 Lisman T, Bongers TN, Adelmeijer J. et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61 DOI: 10.1002/hep.21231.
• 14 Brusilovskaya K, Hofer BS, Simbrunner B. et al. Platelet Function Decreases with Increasing Severity of Liver Cirrhosis and Portal Hypertension-A Prospective Study. Thromb Haemost 2023; 123: 1140-1150 DOI: 10.1055/s-0043-1771187.
• 15 Hofer BS, Brusilovskaya K, Simbrunner B. et al. Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis. Hepatology 2023; DOI: 10.1097/HEP.0000000000000740.
• 16 Nassar A, Huber JP, Stallmann D. et al. Decreased Platelet Aggregation in Patients with Decompensated Liver Cirrhosis and TIPS Implantation. Biomedicines 2023; 11 DOI: 10.3390/biomedicines11072057.
• 17 Alvaro D, Caporaso N, Giannini EG. et al. Procedure-related bleeding risk in patients with cirrhosis and severe thrombocytopenia. Eur J Clin Invest 2021; 51: e13508 DOI: 10.1111/eci.13508.
• 18 Chen Y, Yang C, Huang S. et al. The impact of thrombocytopenia on variceal bleeding in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Sci Rep 2023; 13: 1633 DOI: 10.1038/s41598-023-28646-5.
• 19 Sigal SH, Sherman Z, Jesudian A. Clinical Implications of Thrombocytopenia for the Cirrhotic Patient. Hepat Med 2020; 12: 49-60 DOI: 10.2147/HMER.S244596.
• 20 Intagliata NM, Rahimi RS, Higuera-de-la-Tijera F. et al. Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): An International, Prospective, Multicenter Observational Study. Gastroenterology 2023; 165: 717-732 DOI: 10.1053/j.gastro.2023.05.046.
• 21 Basili S, Raparelli V, Napoleone L. et al. Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study. Am J Gastroenterol 2018; 113: 368-375 DOI: 10.1038/ajg.2017.457.
• 22 Rogalski P, Rogalska-Plonska M, Wroblewski E. et al. Blood platelet function abnormalities in cirrhotic patients with esophageal varices in relation to the variceal bleeding history. Scand J Gastroenterol 2019; 54: 311-318 DOI: 10.1080/00365521.2019.1578822.
• 23 Ibrahim EH, Marzouk SA, Zeid AE. et al. Role of the von Willebrand factor and the VITRO score as predictors for variceal bleeding in patients with hepatitis C-related cirrhosis. Eur J Gastroenterol Hepatol 2019; 31: 241-247 DOI: 10.1097/MEG.0000000000001272.
• 24 Kovalic AJ, Majeed CN, Samji NS. et al. Systematic review with meta-analysis: abnormalities in the international normalised ratio do not correlate with periprocedural bleeding events among patients with cirrhosis. Aliment Pharmacol Ther 2020; 52: 1298-1310 DOI: 10.1111/apt.16078.
• 25 Saner FH, Stern S, Nowak KM. Gerinnungsstörung bei Zirrhose. Gastroenterologie up2date 2021; 17: 25-37 DOI: 10.1055/a-1242-3827.
• 26 Tripodi A, Salerno F, Chantarangkul V. et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-558 DOI: 10.1002/hep.20569.
• 27 Shenoy A, Louissaint J, Shannon C. et al. Viscoelastic Testing Prior to Non-surgical Procedures Reduces Blood Product Use Without Increasing Bleeding Risk in Cirrhosis. Dig Dis Sci 2022; 67: 5290-5299 DOI: 10.1007/s10620-021-07376-6.
• 28 Lisman T, Hernandez-Gea V, Magnusson M. et al. The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. J Thromb Haemost 2021; 19: 1116-1122 DOI: 10.1111/jth.15239.
• 29 Mücke MM, Bruns T, Canbay A. et al. [Use of Thrombopoetin-Receptor-Agonists (TPO-RA) in patients with liver cirrhosis before invasive procedures]. Z Gastroenterol 2023; 61: 1225-1234 DOI: 10.1055/a-1934-1867.
• 30 Schepis F, Turco L, Bianchini M. et al. Prevention and Management of Bleeding Risk Related to Invasive Procedures in Cirrhosis. Semin Liver Dis 2018; 38: 215-229 DOI: 10.1055/s-0038-1660523.
• 31 Pfisterer N, Schwarz M, Jachs M. et al. Endoscopic band ligation is safe despite low platelet count and high INR. Hepatol Int 2023; 17: 1205-1214 DOI: 10.1007/s12072-023-10515-y.
• 32 Gerbes AL, Labenz J, Appenrodt B. et al. [Updated S2k-Guideline „Complications of liver cirrhosis“. German Society of Gastroenterology (DGVS)]. Z Gastroenterol 2019; 57: e168 DOI: 10.1055/a-0928-2800.
• 33 Moster M, Bolliger D. Perioperative Guidelines on Antiplatelet and Anticoagulant Agents: 2022 Update. Curr Anesthesiol Rep 2022; 12: 286-296 DOI: 10.1007/s40140-021-00511-z.
• 34 Drolz A, Ferlitsch A, Fuhrmann V. Management of Coagulopathy during Bleeding and Invasive Procedures in Patients with Liver Failure. Visc Med 2018; 34: 254-258 DOI: 10.1159/000491106.
• 35 Northup PG, Lisman T, Roberts LN. Treatment of bleeding in patients with liver disease. J Thromb Haemost 2021; 19: 1644-1652 DOI: 10.1111/jth.15364.
• 36 Kasper P, Kochanek M, Michels G. [Action algorithm: management of nontraumatic major bleeding in the emergency department]. Med Klin Intensivmed Notfmed 2022; 117: 612-614 DOI: 10.1007/s00063-022-00948-y.
• 37 Collaborators H-IT. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet 2020; 395: 1927-1936 DOI: 10.1016/S0140-6736(20)30848-5.
• 38 Praktiknjo M, Götz M, Trebicka J. Management variköser Blutungen. Die Gastroenterologie 2022; 17: 268-277 DOI: 10.1007/s11377-022-00618-7.
• 39 Götz M, Anders M, Biecker E. et al. [S2k Guideline Gastrointestinal Bleeding – Guideline of the German Society of Gastroenterology DGVS]. Z Gastroenterol 2017; 55: 883-936 DOI: 10.1055/s-0043-116856.
• 40 Götz M, Biecker E, Dechêne A. et al. Addendum zur S2k-Leitlinie Gastrointestinale Blutungen der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2022; 60: 1139-1145 DOI: 10.1055/a-1788-3501.
• 41 Mohanty A, Kapuria D, Canakis A. et al. Fresh frozen plasma transfusion in acute variceal haemorrhage: Results from a multicentre cohort study. Liver Int 2021; 41: 1901-1908 DOI: 10.1111/liv.14936.
• 42 Ambrosino P, Tarantino L, Di Minno G. et al. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost 2017; 117: 139-148 DOI: 10.1160/TH16-06-0450.
• 43 Xing Y, Jiang Y, Xing S. et al. Neutrophil extracellular traps are associated with enhanced procoagulant activity in liver cirrhosis patients with portal vein thrombosis. J Clin Lab Anal 2022; 36 DOI: 10.1002/jcla.24433.
• 44 Northup PG, McMahon MM, Ruhl AP. et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101: 1524-1528 DOI: 10.1111/j.1572-0241.2006.00588.x.
• 45 Zermatten MG, Fraga M, Calderara DB. et al. Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis. JHEP Rep 2020; 2: 100120 DOI: 10.1016/j.jhepr.2020.100120.
• 46 Villa E, Cammà C, Marietta M. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-1260 DOI: 10.1053/j.gastro.2012.07.018.
• 47 Sanchez AP, Turon F, Martinez J. et al. Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial. J Hepatol 2023; 78: S2-S3 DOI: 10.1016/S0168-8278(23)00442-7.
• 48 Senzolo M, Garcia-Pagan JC. A major research gap: The use of anticoagulants in cirrhosis. J Hepatol 2023; 79: 1566-1570 DOI: 10.1016/j.jhep.2023.06.001.
• 49 Elkrief L, Payancé A, Plessier A. et al. Management of splanchnic vein thrombosis. JHEP Rep 2023; 5: 100667 DOI: 10.1016/j.jhepr.2022.100667.
• 50 Senzolo M, Garcia-Tsao G, García-Pagán JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol 2021; 75: 442-453 DOI: 10.1016/j.jhep.2021.04.029.
• 51 Turon F, Driever EG, Baiges A. et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol 2021; 75: 1367-1376 DOI: 10.1016/j.jhep.2021.07.020.
• 52 Driever EG, von Meijenfeldt FA, Adelmeijer J. et al. Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus. Hepatology 2022; 75: 898-911 DOI: 10.1002/hep.32169.
• 53 Guerrero A, Campo Del L, Piscaglia F. et al. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis. J Hepatol 2023; 79: 69-78 DOI: 10.1016/j.jhep.2023.02.023.
• 54 Plessier A, Goria O, Cervoni JP. et al. Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis. NEJM evidence 2022; 1: EVIDoa2200104 DOI: 10.1056/EVIDoa2200104.
• 55 Tripathi D, Stanley AJ, Hayes PC. et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut 2020; 69: 1173-1192 DOI: 10.1136/gutjnl-2019-320221.
• 56 Bettinger D, Thimme R, Schultheiß M. Implantation of transjugular intrahepatic portosystemic shunt (TIPS): indication and patient selection. Curr Opin Gastroenterol 2022; 38: 221-229 DOI: 10.1097/MOG.0000000000000831.
• 57 Tapper EB, Warner MA, Shah RP. et al. Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi. Hepatology 2024; DOI: 10.1097/HEP.0000000000000856.
• 58 Riescher-Tuczkiewicz A, Caldwell SH, Kamath PS. et al. Expert opinion on bleeding risk from invasive procedures in cirrhosis. JHEP Rep 2024; 6: 100986 DOI: 10.1016/j.jhepr.2023.100986.